{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:47:55Z","timestamp":1790740075350,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nodal mature T-cell lymphomas (nMTCL) comprises a heterogeneous group of rare malignancies with aggressive biological behavior and poor prognosis. Epigenetic phenomena, including mutations in genes that control DNA methylation and histone deacetylation, in addition to inactivating mutations in the <jats:italic>RhoA<\/jats:italic> GTPase, play a central role in its pathogenesis and constitute potential new targets for therapeutic intervention. Tumor mutational burden (TMB) reflects the process of clonal evolution, predicts response to anti-cancer therapies and has emerged as a prognostic biomarker in several solid neoplasms; however, its potential prognostic impact remains unknown in nMTCL. In this study, we conducted Sanger sequencing of formalin-fixed paraffin-embedded (FFPE) diagnostic tumor samples using a target-panel to search for recurrent mutations involving the <jats:italic>IDH-1<\/jats:italic>\/<jats:italic>IDH-2<\/jats:italic>, <jats:italic>TET-2<\/jats:italic>, <jats:italic>DNMT3A<\/jats:italic> and <jats:italic>RhoA<\/jats:italic> genes in 59 cases of nMTCL. For the first time, we demonstrated that high-TMB, defined by the presence of \u2265\u2009two mutations involving the aforementioned genes, was associated with decreased overall survival in nMTCL patients treated with CHOP-like regimens. Additionally, high-TMB was correlated with bulky disease, lower overall response rate, and higher mortality. Future studies using larger cohorts may validate our preliminary results that indicate TMB as a potential molecular biomarker associated with adverse prognosis in nMTCL.<\/jats:p>","DOI":"10.1186\/s13148-022-01395-4","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T17:31:47Z","timestamp":1671471107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas"],"prefix":"10.1186","volume":"14","author":[{"given":"Lu\u00eds Alberto","family":"de P\u00e1dua Covas Lage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hebert Fabr\u00edcio","family":"Culler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Carneiro","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cadiele Oliana","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9bora","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"de Oliveira Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"issue":"20","key":"1395_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert E, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"key":"1395_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.06.012","author":"LAPC Lage","year":"2022","unstructured":"Lage LAPC, Brito CV, Barreto GC, Culler HF, Reichert CO, Levy D, et al. Upfront therapy with CHOP plus etoposide in Brazilian nodal PTCL patients: increased toxicity and no survival benefit compared to CHOP regimen. Results of a real-life study from a middle-income country. Clin Lymph Myeloma Leuk. 2022. https:\/\/doi.org\/10.1016\/j.clml.2022.06.012.","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"1395_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-020-00962-x","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhang M. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. Clin Epigenet. 2020. https:\/\/doi.org\/10.1186\/s13148-020-00962-x.","journal-title":"Clin Epigenet"},{"issue":"21","key":"1395_CR4","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","volume":"132","author":"F Lemonnier","year":"2018","unstructured":"Lemonnier F, Dupuis J, Sujobert P, Tournilhac O, Cheminant M, Sarkozy C, et al. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood. 2018;132(21):2305\u20139.","journal-title":"Blood"},{"issue":"16","key":"1395_CR5","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood.2020009004","volume":"137","author":"L Falchi","year":"2021","unstructured":"Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021;137(16):2161\u201370.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1395_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1182\/blood-2020-136023","volume":"136","author":"J Ruan","year":"2020","unstructured":"Ruan J, Moskowitz A, Mehta-Shah N, Sokol L, Chen Z, Rahim R, et al. Multi-center phase II study of oral azacytidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma (PTCL). Blood. 2020;136(Suppl 1):33\u20134. https:\/\/doi.org\/10.1182\/blood-2020-136023.","journal-title":"Blood"},{"key":"1395_CR7","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","volume":"128","author":"D Vallois","year":"2016","unstructured":"Vallois D, Dobay MPD, Morin RD, Lemonnier F, Missiaglia E, Juilland M, et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood. 2016;128:1490\u2013502.","journal-title":"Blood"},{"key":"1395_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/ng.2916","volume":"46","author":"HY Yoo","year":"2014","unstructured":"Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46:371\u20135.","journal-title":"Nat Genet"},{"key":"1395_CR9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/MOH.0000000000000261","volume":"23","author":"JR Cort\u00e9s","year":"2016","unstructured":"Cort\u00e9s JR, Palomero T. The curious origins of angioimmunoblastic T-cell lymphoma. Curr Opin Hematol. 2016;23:434\u201343.","journal-title":"Curr Opin Hematol"},{"key":"1395_CR10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.clml.2021.03.002","volume":"21","author":"PN Nguyen","year":"2021","unstructured":"Nguyen PN, Tran NTB, Nguyen TPX, Ngo TNM, van Lai D, Deel CD, et al. Clinico-pathological implications of RHOA mutations in angioimmunoblastic T-cell lymphoma: a meta-analysis. Clin Lymph Myeloma Leuk. 2021;21:431\u20138.","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"1395_CR11","doi-asserted-by":"publisher","first-page":"103374","DOI":"10.1016\/j.critrevonc.2021.103374","volume":"163","author":"A Addeo","year":"2021","unstructured":"Addeo A, Friedlander A, Banna GL, Weiss GJ. TMB or not TMB as a biomarker: that is the question. Crit Rev Oncol Hematol. 2021;163:103374.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1395_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/21645515.2019.1631136","volume":"16","author":"M Lee","year":"2020","unstructured":"Lee M, Samstein RM, Valero C, Chan TA, Morris LGT. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. Hum Vaccin Immunother. 2020;16(1):112\u20135.","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"1395_CR13","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/s41417-020-0174-y","volume":"27","author":"K Choucair","year":"2020","unstructured":"Choucair K, Morand S, Stanbery L, Edelman G, Dworkin L, Nemunaitis J. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer Gene Ther. 2020;27(12):841\u201353.","journal-title":"Cancer Gene Ther"},{"issue":"6237","key":"1395_CR14","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1126\/science.aaa6806","volume":"348","author":"I Martincorena","year":"2015","unstructured":"Martincorena I, Roshan A, Gerstung M, Ellis P, van Loo P, McLaren S, et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science. 2015;348(6237):880\u20136.","journal-title":"Science"},{"key":"1395_CR15","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"JM Vose","year":"2008","unstructured":"Vose JM, Neumann M, Harris ME. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u201330.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1395_CR16","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00277-019-03731-w","volume":"98","author":"LAPC Lage","year":"2019","unstructured":"Lage LAPC, Hamasaki DT, Moreira FR, Rocha V, Zerbini MCN, Pereira J. Absolute monocyte count is a predictor of overall survival and progression-free survival in nodal peripheral T-cell lymphoma. Ann Hematol. 2019;98(9):2097\u2013102.","journal-title":"Ann Hematol"},{"key":"1395_CR17","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.18632\/oncotarget.27098","volume":"10","author":"LAPC Lage","year":"2019","unstructured":"Lage LAPC, Levy D, Xavier FD, Reis DGC, Costa RO, Gon\u00e7alves MC, et al. Proliferative, pro-inflammatory, and angiogenesis regulator gene expression profile defines prognosis in different histopathological subtypes of nodal peripheral T-cell lymphoma. Oncotarget. 2019;10:5136\u201351.","journal-title":"Oncotarget"},{"key":"1395_CR18","doi-asserted-by":"publisher","first-page":"106794","DOI":"10.1016\/j.leukres.2022.106794","volume":"114","author":"LAPC Lage","year":"2022","unstructured":"Lage LAPC, Brito CV, Levy D, Culler HF, Couto SCF, Oliveira LBA, et al. Diagnostic and prognostic implications of tumor expression of the GATA-3 gene in nodal peripheral T-cell lymphoma (nPTCL): retrospective data from a Latin American cohort. Leuk Res. 2022;114:106794.","journal-title":"Leuk Res"},{"issue":"2","key":"1395_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3233\/CBM-220013","volume":"35","author":"LAPC Lage","year":"2022","unstructured":"Lage LAPC, Barreto GC, Culler HF, Cavalcante JB, Alves LBO, Nardinelli L, et al. TET-2 mutations predict poor outcomes and are associated with unfavorable clinical-biological features in PTCL, not otherwise specified and angioimmunoblastic T-cell lymphoma in Brazilian patients. Cancer Biomark. 2022;35(2):179\u201391.","journal-title":"Cancer Biomark"},{"key":"1395_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/path.945","volume":"195","author":"E Pescarmona","year":"2001","unstructured":"Pescarmona E, Pignoloni P, Puopolo M, Martelli M, Addesso M, Guglielmi C, et al. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome. J Pathol. 2001;195:361\u20136.","journal-title":"J Pathol"},{"key":"1395_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-021-00200-x","volume":"10","author":"Y Ye","year":"2021","unstructured":"Ye Y, Ding N, Mi L, Shi Y, Liu W, Song Y, et al. Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas. Exp Hematol Oncol. 2021;10:1\u201311.","journal-title":"Exp Hematol Oncol"},{"key":"1395_CR22","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1046\/j.1365-2141.2002.03870_3.x","volume":"119","author":"MJ Garc\u00eda","year":"2002","unstructured":"Garc\u00eda MJ, Castrillo JM, Granizo JJ, Carzola A, Rivas C. Clinicopathological correlation, p16\u2013p15 methylation status and outcome predictors in anaplastic large cell lymphoma. Br J Haematol. 2002;119:877\u201388.","journal-title":"Br J Haematol"},{"key":"1395_CR23","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3109\/10428194.2013.858154","volume":"55","author":"R Kansara","year":"2014","unstructured":"Kansara R, Savage KJ. The problem with cyclophosphamide, doxorubicin, vincristine and prednisone for the treatment of peripheral T-cell lymphoma. Leuk Lymphoma. 2014;55:727\u20139.","journal-title":"Leuk Lymphoma"},{"key":"1395_CR24","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomized, phase 3 trial. Lancet. 2019;393:229\u201340.","journal-title":"Lancet"},{"key":"1395_CR25","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood.2019001285","volume":"134","author":"OA O\u2019Connor","year":"2019","unstructured":"O\u2019Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, et al. Oral r-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood. 2019;134:1395\u2013405.","journal-title":"Blood"},{"issue":"22","key":"1395_CR26","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","volume":"360","author":"F Delhommeau","year":"2012","unstructured":"Delhommeau F, Dupont S, della Valle V, James C, Trannoy S, Mass\u00e9 A, et al. Mutation in TET-2 in myeloid cancers. N Engl J Med. 2012;360(22):2289\u2013301.","journal-title":"N Engl J Med"},{"key":"1395_CR27","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1182\/blood-2009-04-215814","volume":"114","author":"O Kosmider","year":"2009","unstructured":"Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, et al. TET-2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009;114:3285\u201391.","journal-title":"Blood"},{"key":"1395_CR28","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1182\/blood-2011-02-339747","volume":"118","author":"WC Chou","year":"2011","unstructured":"Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 2011;118:2803\u20133810.","journal-title":"Blood"},{"key":"1395_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1182\/blood-2010-06-289280","volume":"117","author":"R Itzykson","year":"2011","unstructured":"Itzykson R, Th\u00e9pot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117:403\u201311.","journal-title":"Blood"},{"key":"1395_CR30","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1038\/bcj.2014.83","volume":"4","author":"H Muto","year":"2014","unstructured":"Muto H, Sakata-Yanagimoto M, Nagae G, Shiozawa Y, Miyake Y, Yoshida K, et al. Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice. Blood Cancer J. 2014;4:e264.","journal-title":"Blood Cancer J"},{"issue":"13","key":"1395_CR31","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.3390\/cancers13133119","volume":"13","author":"RT Lawlor","year":"2021","unstructured":"Lawlor RT, Mattiolo P, Mafficine A, Hong SM, Piredda ML, Taormina SV, et al. Tumor mutation burden as a potential biomarker for immunotherapy in pancreatic cancer: systematic review and still-open questions. Cancers. 2021;13(13):3119.","journal-title":"Cancers"},{"key":"1395_CR32","doi-asserted-by":"publisher","first-page":"706652","DOI":"10.3389\/fonc.2021.706652","volume":"11","author":"T Huang","year":"2021","unstructured":"Huang T, Chen X, Zhang H, Liang Y, Li L, Wei H, et al. Prognostic role of tumor mutation burden in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol. 2021;11:706652.","journal-title":"Front Oncol"},{"issue":"1","key":"1395_CR33","doi-asserted-by":"publisher","first-page":"e003091","DOI":"10.1136\/jitc-2021-003091","volume":"10","author":"R Cristescu","year":"2022","unstructured":"Cristescu R, Aurora-Garg D, Albright A, Xu L, Liu XQ, Loboda A, et al. Tumor mutation burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J Immunother Cancer. 2022;10(1):e003091.","journal-title":"J Immunother Cancer"},{"key":"1395_CR34","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1097\/PAS.0000000000000651","volume":"40","author":"R Nagao","year":"2016","unstructured":"Nagao R, Kikuti YY, Carreras J, Kikuchi T, Miyaoka M, Matsushita H, et al. Clinicopathologic analysis of angioimmunoblastic T-cell lymphoma with or without RHOA G17V mutation using formalin-fixed paraffin-embedded sections. Am J Surg Pathol. 2016;40:1041\u201350.","journal-title":"Am J Surg Pathol"},{"key":"1395_CR35","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","volume":"120","author":"F Lemonnier","year":"2021","unstructured":"Lemonnier F, Couronn\u00e9 L, Parrens M, Ja\u00efs JP, Travert M, Lamant L, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2021;120:1466\u20139.","journal-title":"Blood"},{"key":"1395_CR36","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","volume":"126","author":"C Wang","year":"2015","unstructured":"Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood. 2015;126:1741\u201352.","journal-title":"Blood"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-022-01395-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-022-01395-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-022-01395-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T17:31:49Z","timestamp":1671471109000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-022-01395-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1395"],"URL":"https:\/\/doi.org\/10.1186\/s13148-022-01395-4","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"24 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the local Ethic Committee (University of S\u00e3o Paulo) in 2013, number CAPPesq 02975012.0.0000.0068. All procedures followed were in accordance with ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. The application of the Free and Informed Consent Form (FICF) was waived by the CAPPESQ \u2013 Ethics Committee for the Analysis of Research Projects at Hospital das Cl\u00ednicas, Faculty of Medicine, University of S\u00e3o Paulo (USP).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}